title: Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
abstract: OBJECTIVE
  We aimed to determine the optimal cut-off of the immunochemical faecal occult blood test (iFOBT) by using cost-effectiveness analysis.
  
  
  METHODS
  A total of 22,672 subjects aged 50 years or older were invited to have an uptake of iFOBT. We collected data from screen-detected cases for the cut-off above 100 ng/mL and obtained interval cancers from a nationwide cancer registry for a cut-off below 100 ng/mL. We found a total of 65 colorectal cancer (CRC) cases, including 43 detected by screen and 22 diagnosed between screens (interval cases). The optimal cut-off was first determined by receiver operating characteristics (ROC) curve analysis. Formal economic evaluation was further applied to identifying the optimal cut-off by assessing the minimum incremental cost-effectiveness ratio (ICER), an indicator for cost per life year gained (effectiveness), given a series of cut-offs of iFOBT, ranging from 30 to 200 ng/mL compared with no screening.
  
  
  RESULTS
  ROC curve analysis found the optimal cut-off of iFOBT to be 100 ng/mL at which the sensitivity, false-positive and odds of being affected given a positive result were 81.5% (70.2%-89.2%), 5.7% (5.4%-6.0%) and 1.24 (1.19-1.32), respectively. The area under ROC curve was 0.87 (0.81-0.93). In economic appraisal, the screening programme irrespective of any cut-off dominated (less cost and more effectiveness) over the control group. The optimal cut-off (the lowest ICER) was 110 ng/mL at which an average of 0.054 life year was gained and that of 950 ($US) was saved.
  
  
  CONCLUSIONS
  We used cost-effectiveness to identify 110 ng/mL as the optimal cut-off of iFOBT in a Taiwanese population-based screening for CRC. Our model provides a useful approach for health policy-makers in designing population-based screening for CRC to determine the optimal cut-off of iFOBT when cost and effectiveness need to be taken into account.
authors: Division of Clinical Breast Cancer and Cancer Biology, Changhua Christian Hospital, 135 Nanhsiao Street, Changhua 500, Taiwan, ROC.
authors: Li-Sheng
authors: LS
authors: Chen
authors: Chao-Sheng
authors: CS
authors: Liao
authors: Shu-Hui
authors: SH
authors: Chang
authors: Hsin-Chih
authors: HC
authors: Lai
authors: Tony Hsiu-Hsi
authors: TH
authors: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000191:economics; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D005260:Female; D006801:Humans; D007120:Immunochemistry / Q000191:economics / Q000379:methods; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000379:methods / Q000592:standards; D008875:Middle Aged; D009780:Occult Blood; D011153:Population; D012372:ROC Curve; D012016:Reference Values